Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acrux ( (AU:ACR) ) has provided an update.
Acrux Limited has received a $0.4 million advance from Radium Capital as part of its FY26 R&D Tax Incentive, representing 80% of the estimated rebate for the quarter ending September 2025. This funding, which incurs a 17% annual interest, will support the development of Acrux’s products and manage working capital, highlighting the company’s ongoing commitment to innovation and financial strategy.
More about Acrux
Acrux is a specialty pharmaceutical company with a strong track record in developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company has successfully marketed several products globally, particularly focusing on the United States.
Average Trading Volume: 462,736
Technical Sentiment Signal: Sell
Current Market Cap: A$6.55M
See more data about ACR stock on TipRanks’ Stock Analysis page.